Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Phase 1positive177Lu-RAD202Positive

AI Analysis

Summary

Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to advance the 177Lu-RAD202 Phase 1 HEAT trial to Cohort 4 with a 180mCi dose level in patients with HER2+ advanced solid tumors.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Data Safety and Monitoring Committee recommended advancement to Cohort 4 with 180mCi dose level

Importance:5/10

Sentiment:

0.75

Phase 1DSMC positive recommendationdose escalationHER2+ tumorsradiopharmaceutical

Related Companies

$SLDB

Read the original article

Published by GlobeNewswire Clinical Studies on August 20, 2026 11:00 AM

Read Original